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Background/aims: Radiosurgery is an effective
treatment for trigeminal neuralgia (TN) with
minimal complications. Most experience is based
on gamma knife radiosurgery (GKRS) and to a
lesser extent on linear accelerators. 
Methods: We report our initial experience in
17 patients with TN treated by an adapted linear
accelerator using the BrainLab® system. The
trigeminal root entry zone immediately adjacent
to the pons (target volume: 0.01–0.09 cm3, mean:
0.02 cm3) was targeted by use of a multileaf colli-
mator to deliver 40–45 Gy to the 80% isodose
(dose max 50–56 Gy). Median follow-up was 
12 months (range: 1–60). 
Results: All patients reported some initial im-
provement in level of pain after treatment (mean
time: 1 month). Initial pain responses were as
 follows: 6 patients (35%) had complete pain relief
and required no medication, 6 (35%)  had occa-
sional pain but were off medication, and 5 (30%)
experienced partial relief of pain but still required
medication, usually in lower doses. Five patients
(29%) who experienced  initial pain relief had
 recurrences ranging from 4–13 months after pro-
cedure. There were no major or minor complica-
tions of radiosurgery except one case of mild
 facial itching. 
Conclusion: Stereotactic radiosurgery using a
linear accelerator appears to be effective and can
be a favourable alternative to other procedures,
including GKRS. The procedure is very safe and
side effects are rare and minor. However, a ran-
domised trial with a longer follow-up comparing
radiosurgery to other surgical procedures is
needed to assess the long term effectiveness of
this treatment.
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Summary
Trigeminal neuralgia (TN) is the best defined
and one of the most common causes of facial pain,
especially in the elderly. It is described as sudden,
usually one-sided, severe, brief, sharp or lancinat-
ing, recurrent episodes of spontaneous or stimu-
lation-triggered pain in the territory of one or
more branches of the trigeminal nerve [1, 2].
Most cases of TN are caused by compression of
the trigeminal nerve root, usually within a few
millimeters of entry into the pons, the root entry
zone (REZ) [3]. The mechanism by which com-
pression of the nerve causes symptoms appears to
be related to demyelination in a circumscribed
area around the compression [4, 5]. Precisely how
demyelination results in the symptoms of TN is
not entirely clear. Pharmacological therapy is the
initial treatment in most patients with TN not
caused by a structural lesion (multiple sclerosis or
tumour mass). Surgery is confined to patients who
are refractory to medical therapy or if the latter
causes side effects which prevent its use. A variety
of surgical procedures may relieve symptoms in
patients with TN refractory to drug therapy.
They include microvascular decompression, ra-
diofrequency rhizotomy, glycerol rhizolysis and
balloon compression. Microvascular decompres-
sion is invasive, although the overall mortality and
complication rate are low and the procedure is
 associated with the best long-term outcome [6].
Rhizotomy is less invasive and associated with a
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high initial response rate, but recurrence is com-
mon and the incidence of facial numbness is
higher than with microvascular decompression.
Stereotactic radiosurgery is a procedure that
can be attempted in TN patients if drug therapy
and/or surgery fail. In addition, it causes few side
effects, the principal being facial numbness. The
commonest experience in this field is based on
gamma knife radiosurgery (GKRS) [7–16]. Re-
ports on radiosurgery using a linear accelerator
(LINAC) in the treatment of TN conclude that
treatment with LINAC can be as effective as
GKRS [17–23]. 
To contribute to the data on LINAC treat-
ment for TN we report our initial experience of
17 TN patients treated by dedicated linear accel-
erator using the BrainLab® system.
Patient profile
From 2000 to 2005, 17 patients with TN were
treated in the Radiation Oncology Department of the
CHUV, Lausanne, Switzerland. Patient characteristics
are shown in table 1. Median age at the time of radio-
surgery was 71 years (range: 48–77). In the majority of
patients TN had failed to respond to medical therapy,
 either because the TN was refractory to medication or
the patient experienced side effects which precluded the
use of the medication. Ten patients (59%) had undergone
one or more previous unsuccessful procedures including
microvascular decompression, thermal rhizotomy or
 retrogasserian glycerol rhizolysis. Seven patients under-
went radiosurgery as their primary procedure after med-
ical failure.
One patient had documented multiple sclerosis
(MS) and one probable MS based on MRI scan. There
was one case of atypical TN with neck pain.
Patient preparation and immobilisation
One day before the radiosurgical procedure all
 patients underwent non-stereotactic 3D inversion-recov-
ery-based T1-weighted (magnetisation-prepared rapid
acquisition with gradient-echo [MPRAGE]) magnetic
resonance imaging (MRI) with gadolinium contrast en-
hancement and three-dimensional T2-weighted volume
acquisitions divided into 1 mm slices before stereotactic
frame placement through the trigeminal nerve root entry
zone (REZ). On the day of radiosurgery a BrainLab®
stereotactic frame was placed on the patient’s head after
local infiltration of an anaesthetic agent.
For treatment planning a contrast enhanced treat-
ment planning CT scan was performed with 2.5 mm slice
thickness with the stereotactic frame in place.
Treatment planning and delivery
CT and MRI image registration was performed
using an image fusion software tool of the stereotactic
planning system (BrainSCAN System, BrainLab®).The
target volume was the trigeminal root entry zone (REZ),
immediately adjacent to the pons, and ranged from 0.01
to 0.09 cm3 (mean: 0.02 cm3). The planning target vol-
ume (PTV), mimicking the 6 mm collimator used for the
treatment, was placed at the REZ and 50 to 56 Gy were
prescribed to isocentre resulting in 40 to 45 Gy to the
80% isodose surface, so that the 30 Gy isodose surface
was tangential to the brainstem (fig. 1). One isocentre was
used for radiosurgery, which was delivered with an aver-
age number of 18 fixed, non-coplanar conformal beams
(range: 17–24). Treatments were performed with a 6-MV
photon beam provided by a Primus linear accelerator
Material and methods
Figure 1
Axial reconstruction
showing target
 selection at the root
entry zone of the fifth
cranial nerve.
Total Number 17
Age (years) Median 71
Range 48–77
Gender Male 9
Female 8
Duration of pain (years) Median 12
Range 0.5–20
Location of neuralgia Right 11
Left 6
Bilateral 1
Number of dermatomes involved 1 (V1, V2, V3) 7 (1.5.1)
2 (V1–V2, V2–V3) 6 (3.3)
3 (V1–V3) 4
Multiple Sclerosis 2*
Prior invasive treatment Yes 10
No 7
Type of prior procedure
Microvascular decompression 6
Thermal rhizotomy 5
Alcoholisation 1
Number of invasive procedure 1 5
2 3
3 or more 2
Follow-up (months) Median 12
Range 1–60
*: one patient had probable MS based on MRI scan
Table 1
Patients  characteristics.
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(Siemens), using the BrainLab® system with a micromulti-
leaf collimator.
Pain evaluation
Pain before and after radiosurgery was scored ac-
cording to the Barrow Neurosurgical Institute (BNI)
pain intensity scale (table 2) [14]. Before radiosurgery, 
6 patients had severe pain or no improvement with med-
ication (BNI score V), 10 patients had some pain not
 adequately controlled with medication (BNI score IV), 
1 patient had pain adequately controlled with medication
(BNI score III) but wished to stop the drugs. 
Follow-up
Median follow-up was 12 months (range: 1–60). No
patients were lost to follow-up. Patients were usually seen
initially 6–12 weeks after treatment by neurosurgeons to
evaluate the initial treatment response and complications.
If they were pain-free at that time, they were subse-
quently seen regularly by their general practitioner
and/or neurologist. If they were not pain-free and/or still
required medication at the first neurosurgical evaluation,
they were usually seen again by neurosurgeons to further
evaluate the need of medication or of another surgical
procedure in the event of treatment failure. MRI was not
usually performed for follow-up.
Initial pain relief
All patients reported some initial improve-
ment in the level of pain after treatment. The
mean time lapse to pain improvement was one
month (range: 2 weeks to 6 months). Initial pain
responses were as follows: 6 patients (35%) had
complete pain relief and required no medication
(BNI score I), 6 (35%) had occasional pain but did
not require medication (BNI score II), 5 (30%)
had partial relief of pain and still required some
medication (BNI score III), usually in lower
doses. The degree of initial pain did not influence
the pain response rate.
Durability of pain response
The patients’ BNI pain scores before and
after radiosurgery are summarised in table 3. At
last follow-up, 5 patients had BNI score I (median
follow-up 8 months; range 2–60), 2 patients had
BNI score II (median follow-up 14 months; range
12–16), 5 patients had BNI score III (median
 follow-up 21 months; range 1–45). Five patients
(29%) with initial pain relief (BNI score I–III)
had a recurrence (BNI score IV) 4–13 months
after radiosurgery (mean 7 months). Recurrence
was defined as an initial improvement followed by
deterioration of BNI score. Of the 5 patients with
a recurrence, four had undergone one or more
previous unsuccessful procedures prior to radio-
surgery. They required further treatment, usually
consisting of thermal rhizotomy. One of them
suffering a recurrence 12 months after radio-
surgery underwent thermal rhizotomy 15 months
after radiosurgery and was pain-free again 
2 months after that procedure.
Results
Score
I No trigeminal pain, no medication
II Occasional pain, not requiring medication
III Some pain, adequately controlled with medication
IV Some pain, not adequately controlled with medication
V Severe pain/no pain relief
Table 2
Barrow Neurological
Institute (BNI) pain
intensity score [13].
Patient no BNI BNI after radiosurgery Follow-up
before treatment at 6–12 weeks at last follow-up (months)
1 4 3 4 12
2 5 2 2 12
3 4 1 1 11
4 5 3 3 45
5 3 1 3 20
6 5 3 1 17
7 5 2 3 21
8 5 2 1 60
9 4 2 4 12
10 4 1 1 8
11 4 3 3 28
12 4 1 1 6
13 4 1 1 2
14 4 3 3 1
15 4 1 4 5
16 5 2 4 5
17 4 2 2 16
Table 3
BNI pain score 
before and after
 radiosurgery.
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Complications
No immediate side effect occurred in any of
the patients. At last follow-up, no complications
of radiosurgery were seen except for one case of
mild facial itching. Two patients already had facial
numbness prior to radiosurgery which was related
to a previous procedure, but none developed
 facial numbness consecutive to radiosurgery.
Radiosurgery is an attractive alternative to
open surgery because it is performed on an out-pa-
tient basis, the treatment is well tolerated and mor-
bidity is low. This modality is particularly suitable
for the treatment of  patients who are poor candi-
dates for surgery, in whom other therapies have
failed, or who are unwilling to undergo an  invasive
procedure. Some investigators have explored the
use of GKRS as the primary treatment for TN in
elderly patients or in those with significant comor-
bidities [2, 7, 9]. They concluded that patients with
TN who are treated with GKRS as primary man-
agement experience better pain relief than those
treated with GKRS as secondary management. Re-
ports on earlier clinical studies have demonstrated
the efficacy of GKRS in targeting the root entry
zone of the trigeminal nerve and thus alleviating
pain in many patients with TN [7, 9, 10, 14]. Ap-
proximately 75% of patients report complete relief
initially and for the first three months [24], but this
 number decreases to 50% after three years. Less
than 50% of patients can permanently stop drug
therapy after surgery. Sensory disturbances includ-
ing numbness, paresthesias and dysesthesias are the
most frequent complications.  Patients who fail to
respond to radiosurgery or who experience recur-
rence of symptoms may respond to repeat treat-
ment [13, 15, 25]. 
Recently linear accelerator (LINAC) radio-
surgery for TN has also been shown to be safe
and effective as a primary non-invasive treatment
for  selected patients with essential TN [19]. In
our study the results in terms of pain relief are
comparable with the data obtained in the litera-
ture with both GKRS and LINAC. Interestingly,
the complication rate in our small series (one case
of facial itching) was much lower than is usually
reported in the literature (3–29% of facial numb-
ness) with GK or LINAC radiosurgery. None of
our patients  developed facial numbness after
 radiosurgery. Previous reports have shown a
 correlation between  facial numbness and im-
provement in pain score [12–14, 26]. In a recent
study by McNatt et al. [12], 77% of patients 
who developed new-onset facial numbness had
favourable outcomes, with BNI pain scores of III
or better, whereas only 30% of patients who did
not develop facial numbness had favour able out-
comes. In this study, we were not able to show a
correlation between pain improvement and facial
numbness after radiosurgery.
In our centre we used a very proximal target
 located 2–4 mm from the REZ with a central dose
of 50–56 Gy. Some centres use a very anterior
 target, located immediately posterior to the
gasserian ganglion as originally described by
Régis et al. [27] with a maximum dose ranging
from 70–90 Gy. This difference in dose prescrip-
tion and in target localisation might in part ex-
plain the lower incidence of complications in our
series when compared to others’ reports. A longer
follow-up and a larger population are required to
compare results in terms of pain outcome and
morbidity with the GK experience.
As in most studies in this field, the median
 follow-up has been less than 2 years. Because pain
improvement usually occurs in the first few
months after treatment (mean: 1–2 months [9–11]),
the initial pain response can be adequately quan -
tified. Moreover, most recurrences occur in the
first year after treatment and thus the majority 
of cases can usually be reported. However, due to
the short  follow-up period in this study late treat-
ment failure and long-term outcome cannot be
estimated. In our series, with a median follow-up
of 12 months, the recurrence rate was 29% and
was thus in the middle range of recurrence rates
reported in the literature (5–63%; median 15%).
However, given the slightly shorter follow-up
 period in our study compared with the mean
 follow-up period in other studies, the rate of re-
currence may be underestimated. Our results are
also in agreement with the data in the  literature
showing that excellent or good relief (at least 50%
reduction in pain and less medication) is more
likely to occur in patients treated by radiosurgery
as primary management [7]. Indeed, 4 out of 5  pa -
tients with a recurrence had undergone one or
more previous unsuccessful procedures prior to
radiosurgery.
Because TN and pain in general is a subjec-
tive symptom which can be influenced by many
factors including duration of disease, age, gender,
tolerance capacity and psychology, studies evalu-
ating successful interventions for pain depend
largely on patients’ subjective evaluation. Unfor-
tunately there is no precise pain scale that can be
applied and direct comparison between different
studies is difficult.
Stereotactic radiosurgery using a linear accel-
erator seems to be effective and may offer a
favour able alternative to other procedures includ-
ing GKRS. The procedure is also very safe and
side  effects are  rare and minor, even with a high
dose. Depending on the target and some other
dosimetric parameters, a dose of 70 Gy to the
maximum point is currently recommended for
the LINAC-based system and the gamma knife
Discussion
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system, with pain control rates of 35% to 74%.
However, a randomised trial with a longer follow-
up comparing radiosurgery to other surgical pro-
cedures is needed to assess the long-term effec-
tiveness of this treatment. 
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